No­var­tis backs Gami­da Cell’s $40M raise to fund a loom­ing PhI­II study, mar­ket­ing and man­u­fac­tur­ing prep

Is­rael’s Gami­da Cell now has the cash it needs to ex­e­cute on a late-stage tri­al for its ex­per­i­men­tal cell graft, which it hopes can be OK’d for use when the right bone mar­row donor can’t be found for pa­tients suf­fer­ing from leukemia and lym­phoma.

Long­time backer No­var­tis jumped back in on this raise, join­ing lead in­vestor Shav­it Cap­i­tal along with new in­vestors VMS In­vest­ment Group and Is­rael Biotech Fund and cur­rent in­vestors Clal Biotech­nol­o­gy In­dus­tries and Is­rael Health­Care Ven­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.